ClinicalTrials.gg
CompletedNCT02387853Updated Mar 10, 2025Results posted

Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

A Phase 2 interventional study of LEO 90100 in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 9 sites in 4 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
117
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
28th of 47
117 · median 200
Started
2016
the only one that year
Phase 2
9 of 47
none open now
Registered
29th of 47
by date
Lead sponsor
22 of 47
LEO Pharma

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 28th largest by enrollment, is the only one that started in 2016, is one of 9 in phase 2, and was the 29th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Psoriasis vulgaris on trunk and/or limbs affecting at least 2% BSA.
  • Psoriasis vulgaris on the scalp affecting at least 10% of total scalp area.
  • A total psoriatic involvement on trunk, limbs and scalp not exceeding 30% BSA.
  • PGA score of at least mild on trunk and/or limbs at SV1, SV2 and V1.
  • PGA score of at least mild on scalp at SV1, SV2 and V1.
  • A serum albumin-corrected calcium below the upper reference limit at SV2.

Inclusion Criteria (for subjects performing HPA axis assessment)

  • Psoriasis vulgaris on trunk and/or limbs affecting at least 10% BSA.
  • Psoriasis vulgaris on the scalp affecting at least 20% of total scalp area.
  • PGA score of at least moderate on trunk and limbs at SV1, SV2 and V1.
  • PGA score of at least moderate on scalp at SV1, SV2 and V1.
  • Normal HPA axis function at SV2 (serum cortisol concentration above 5 mcg/dl before ACTH challenge and serum cortisol concentration above 18 mcg/dl 30 minutes after ACTH challenge).

Exclusion criteria

Exclusion Criteria (all subjects):

  • A history of to any component of LEO 90100.
  • Systemic treatment with biological therapies (marketed or not marketed), with a possible effect on scalp and/or body psoriasis within the following time period prior to V1 and during the trial:

    1. etanercept - within 4 weeks prior to V1
    2. adalimumab, infliximab - within 2 months prior to V1
    3. ustekinumab - within 4 months prior to V1
    4. experimental products - within 4 weeks/5 half-lives (whichever is longer) prior to V1
  • Systemic treatment with therapies other than biologicals, with a possible effect on scalp and/or body psoriasis (e.g. methotrexate, retinoids, ) within 4 weeks prior to V1 or during the trial.
  • PUVA therapy within 4 weeks prior to V1.
  • UVB therapy within 2 weeks prior to V1 or during the trial.

Exclusion Criteria (for subjects performing HPA axis assessment):

  • A history of serious allergy, allergic asthma or serious allergic skin rash.
  • Known or suspected hypersensitivity to any component of CORTROSYN® (including ACTH/cosyntropin/tetracosactide)
  • Systemic treatment with (including inhaled and nasal steroids) within 12 weeks prior to SV2 or during the trial.
  • Oestrogen therapy (including ) or any other medication known to affect cortisol levels or HPA axis integrity within 4 weeks prior to SV2 or during the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    LEO 90100

    Drug: LEO 90100

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Events (AEs)

    Number of subjects with adverse events in the safety analysis set, defined by excluding subjects from the full analysis set who either received no treatment with the IMP and/or for whom no post-baseline safety evaluations are available.

    Time frame: From Week -1 to Week 8

  2. Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After ACTH-challenge at Week 4

    Number of subjects with serum cortisol concentration of ≤18 mcg/dl at 30 minutes after ACTH-challenge at Week 4 in the per protocol analysis set, defined as all subjects from the full analysis set who were in the HPA axis cohort but excluding subjects who did not receive any treatment with the IMP, did not provide any results for the HPA axis test at Week 4, or did not meet the inclusion criterion concerning evidence of normal adrenal function at baseline.

    Time frame: 30 minutes after ACTH-challenge at Week 4

  3. Change in Albumin-corrected Serum Calcium From Baseline to Week 4

    Change in albumin-corrected serum calcium from baseline to Week 4 in safety analysis set. The safety analysis set, defined by excluding subjects from the full analysis set who either received no treatment with the IMP and/or for whom no post-baseline safety evaluations are available.

    Time frame: From baseline to Week 4

  4. Change in Calcium Excretion in 24-hour Urine From Baseline to Week 4

    Change in calcium excretion in 24-hour urine collection from baseline to Week 4 in the 24-hour urine HPA set, defined as all subjects in the safety analysis set. The safety analysis set is defined, according to the Consolidated Trial Protocol, by excluding subjects from the full analysis set who either received no treatment with the IMP and/or for whom no post-baseline safety evaluations are available.

    Time frame: From baseline to Week 4

  5. Change in Calcium:Creatinine Ratio in 24-hour Urine From Baseline to Week 4

    Change in calcium:creatinine ratio in 24-hour urine collection from baseline to Week 4 in the 24-hour urine in HPA set, defined as all subjects in the safety analysis set who underwent HPA-axis testing.

    Time frame: From baseline to Week 4

Secondary outcomes

  1. Number of Subjects With Serum Cortisol Concentration ≤18 mcg/dL at Both 30 and 60 Minutes After ACTH-challenge at Week 4

    Number of subjects with serum cortisol concentration ≤18 mcg/dL at both 30 and 60 minutes after ACTH-challenge at Week 4 in the per protocol analysis set, defined as all subjects from the full analysis set who were in the HPA axis cohort but excluding subjects who did not receive any treatment with the IMP, did not provide any results for the HPA axis test at Week 4, or did not meet the inclusion criterion concerning evidence of normal adrenal function at baseline.

    Time frame: 30 and 60 minutes after ACTH-challenge at Week 4

  2. Change in Calcium:Creatinine Ratio in Spot Urine Samples From Baseline to Week 4

    Change in calcium:creatinine ratio in spot urine samples from baseline to Week 4 in the spot urine non-HPA set, defined as all subjects in the safety analysis set who did not undergo HPA-axis testing.

    Time frame: From baseline to Week 4

  3. Number of Subjects With 'Treatment Success' According to Physician's Global Assessment (PGA) on Body

    Number of subjects with 'treatment success' according to Physician's Global Assessment (PGA) on Body in the full analysis set, defined as the 106 subjects assigned to treatment. Treatment success was defined as 'clear' or 'almost clear' for subjects with at least 'moderate' disease at baseline according to the PGA, and defined as 'clear' for subjects with mild disease at baseline according to the PGA.

    Time frame: Week 4

  4. Number of Subjects With 'Treatment Success' According to Physician's Global Assessment (PGA) on Scalp

    Number of subjects with 'treatment success' according to Physician's Global Assessment (PGA) on Scalp in the full analysis set, defined as the 106 subjects assigned to treatment. Treatment success was defined as 'clear' or 'almost clear' for subjects with at least 'moderate' disease at baseline according to the PGA, and defined as 'clear' for subjects with mild disease at baseline according to the PGA.

    Time frame: Week 4

  5. Percentage Change in PASI From Baseline to Week 4

    Percentage change in Psoriasis area and severity index (PASI) score from baseline to Week 4. Psoriasis area and severity index (PASI) assesses extent and severity of clinical signs of psoriasis vulgaris. Body surface is divided in 4 ares: head (incl. neck), arms (incl. hands), trunk (incl. flexures) and legs (incl. buttocks and feet). Each area is scored from 0-6 for extent of psoriasis and from 0-4 for redness, thickness, and scaliness, and an area PASI score is calculated. The total PASI score is calculated from each area's score. The PASI score ranges from 0 (clear skin) to 72 (maximum disease), a PASI score higher than 10 generally corresponds to moderate-to-severe disease.

    Time frame: From baseline to Week 4

  6. Number of Subjects With 'Treatment Success' According to the Subject's Global Assessment of Disease Severity on the Body at Week 4

    Number of subjects with 'treatment success' according to the Subject's Global Assessment of disease severity on the body at Week 4 in the full analysis set, defined as the 106 subjects assigned to treatment. Treatment success was defined as 'clear' or 'very mild' according to the Subject's Global Assessment of disease severity.

    Time frame: Week 4

  7. Number of Subjects With 'Treatment Success' According to the Subject's Global Assessment of Disease Severity on the Scalp at Week 4

    Number of subjects with 'treatment success' according to the Subject's Global Assessment of disease severity on the scalp at Week 4 in the full analysis set, defined as the 106 subjects assigned to treatment. Treatment success was defined as 'clear' or 'very mild' according to the Subject's Global Assessment of disease severity.

    Time frame: Week 4

  8. Change in Itch as Assessed on a Visual Analog Scale (VAS) From Baseline to Week 4

    Change in itch as assessed on a visual analog scale (VAS) from baseline to Week 4 in the full analysis set, defined as the 106 subjects assigned to treatment. The assessments were made on a 100 mm (100 mm = 10 cm) horizontal VAS anchored at 0 ('no itch at all') and 10 ('worst itch you can imagine'). Subjects were asked to put a vertical line on the scale at the spot he/she felt best reflected the maximal itch intensity during the last 24 hours. The distance from 0 to the subject's indication line was measured in mm, thus higher scores indicated a worse outcome.

    Time frame: From baseline to Week 4

07

Results

Posted Jan 15, 2019

Participant flow

Participant flow — Overall Study
MilestoneLEO 90100
Started106
Completed103
Not completed3

Outcome measures

PrimaryNumber of Subjects With Adverse Events (AEs)

Number of subjects with adverse events in the safety analysis set, defined by excluding subjects from the full analysis set who either received no treatment with the IMP and/or for whom no post-baseline safety evaluations are available.

Time frame:
From Week -1 to Week 8
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events (AEs)
ParticipantsLEO 90100
Upper respiratory tract infection8
Nasopharyngitis4
Folliculitis1
Impetigo1
Oral herpes1
Pharyngitis1
Pulpitis dental1
Rhinitis1
Acne2
Erythema1
Pruritus generalised1
Psoriasis1
Skin reaction1
Application site pain1
Product physical consistency issue1
Arthralgia1
Myalgia1
Myopia1
Arthropod bite1
Haemangioma of liver1
Skin neoplasm excision1
PrimaryNumber of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After ACTH-challenge at Week 4

Number of subjects with serum cortisol concentration of ≤18 mcg/dl at 30 minutes after ACTH-challenge at Week 4 in the per protocol analysis set, defined as all subjects from the full analysis set who were in the HPA axis cohort but excluding subjects who did not receive any treatment with the IMP, did not provide any results for the HPA axis test at Week 4, or did not meet the inclusion criterion concerning evidence of normal adrenal function at baseline.

Time frame:
30 minutes after ACTH-challenge at Week 4
Reported as:
Count of participants · Participants
Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After ACTH-challenge at Week 4
ParticipantsLEO 90100
Serum cortisol equal to or below 18 mcg/dl3
Serum cortisol above 18 mcg/dl30
PrimaryChange in Albumin-corrected Serum Calcium From Baseline to Week 4

Change in albumin-corrected serum calcium from baseline to Week 4 in safety analysis set. The safety analysis set, defined by excluding subjects from the full analysis set who either received no treatment with the IMP and/or for whom no post-baseline safety evaluations are available.

Time frame:
From baseline to Week 4
Reported as:
Mean · mmol/L
Change in Albumin-corrected Serum Calcium From Baseline to Week 4
mmol/LLEO 90100
Change in Albumin-corrected Serum Calcium From Baseline to Week 4-0.016 ± 0.119
PrimaryChange in Calcium Excretion in 24-hour Urine From Baseline to Week 4

Change in calcium excretion in 24-hour urine collection from baseline to Week 4 in the 24-hour urine HPA set, defined as all subjects in the safety analysis set. The safety analysis set is defined, according to the Consolidated Trial Protocol, by excluding subjects from the full analysis set who either received no treatment with the IMP and/or for whom no post-baseline safety evaluations are available.

Time frame:
From baseline to Week 4
Reported as:
Mean · mmol/24hr
Change in Calcium Excretion in 24-hour Urine From Baseline to Week 4
mmol/24hrLEO 90100
Change in Calcium Excretion in 24-hour Urine From Baseline to Week 4-0.335 ± 2.076
PrimaryChange in Calcium:Creatinine Ratio in 24-hour Urine From Baseline to Week 4

Change in calcium:creatinine ratio in 24-hour urine collection from baseline to Week 4 in the 24-hour urine in HPA set, defined as all subjects in the safety analysis set who underwent HPA-axis testing.

Time frame:
From baseline to Week 4
Reported as:
Mean · mmol/g
Change in Calcium:Creatinine Ratio in 24-hour Urine From Baseline to Week 4
mmol/gLEO 90100
Change in Calcium:Creatinine Ratio in 24-hour Urine From Baseline to Week 4-0.2892 ± 2.1185
SecondaryNumber of Subjects With Serum Cortisol Concentration ≤18 mcg/dL at Both 30 and 60 Minutes After ACTH-challenge at Week 4

Number of subjects with serum cortisol concentration ≤18 mcg/dL at both 30 and 60 minutes after ACTH-challenge at Week 4 in the per protocol analysis set, defined as all subjects from the full analysis set who were in the HPA axis cohort but excluding subjects who did not receive any treatment with the IMP, did not provide any results for the HPA axis test at Week 4, or did not meet the inclusion criterion concerning evidence of normal adrenal function at baseline.

Time frame:
30 and 60 minutes after ACTH-challenge at Week 4
Reported as:
Count of participants · Participants
Number of Subjects With Serum Cortisol Concentration ≤18 mcg/dL at Both 30 and 60 Minutes After ACTH-challenge at Week 4
ParticipantsLEO 90100
Serum cortisol equal to or below 18 mcg/dL1
Serum cortisol above 18 mcg/dl32
SecondaryChange in Calcium:Creatinine Ratio in Spot Urine Samples From Baseline to Week 4

Change in calcium:creatinine ratio in spot urine samples from baseline to Week 4 in the spot urine non-HPA set, defined as all subjects in the safety analysis set who did not undergo HPA-axis testing.

Time frame:
From baseline to Week 4
Reported as:
Mean · mmol/g
Change in Calcium:Creatinine Ratio in Spot Urine Samples From Baseline to Week 4
mmol/gLEO 90100
Change in Calcium:Creatinine Ratio in Spot Urine Samples From Baseline to Week 40.4620 ± 1.8892
SecondaryNumber of Subjects With 'Treatment Success' According to Physician's Global Assessment (PGA) on Body

Number of subjects with 'treatment success' according to Physician's Global Assessment (PGA) on Body in the full analysis set, defined as the 106 subjects assigned to treatment. Treatment success was defined as 'clear' or 'almost clear' for subjects with at least 'moderate' disease at baseline according to the PGA, and defined as 'clear' for subjects with mild disease at baseline according to the PGA.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Subjects With 'Treatment Success' According to Physician's Global Assessment (PGA) on Body
ParticipantsLEO 90100
Yes74
No29
SecondaryNumber of Subjects With 'Treatment Success' According to Physician's Global Assessment (PGA) on Scalp

Number of subjects with 'treatment success' according to Physician's Global Assessment (PGA) on Scalp in the full analysis set, defined as the 106 subjects assigned to treatment. Treatment success was defined as 'clear' or 'almost clear' for subjects with at least 'moderate' disease at baseline according to the PGA, and defined as 'clear' for subjects with mild disease at baseline according to the PGA.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Subjects With 'Treatment Success' According to Physician's Global Assessment (PGA) on Scalp
ParticipantsLEO 90100
Yes78
No25
SecondaryPercentage Change in PASI From Baseline to Week 4

Percentage change in Psoriasis area and severity index (PASI) score from baseline to Week 4. Psoriasis area and severity index (PASI) assesses extent and severity of clinical signs of psoriasis vulgaris. Body surface is divided in 4 ares: head (incl. neck), arms (incl. hands), trunk (incl. flexures) and legs (incl. buttocks and feet). Each area is scored from 0-6 for extent of psoriasis and from 0-4 for redness, thickness, and scaliness, and an area PASI score is calculated. The total PASI score is calculated from each area's score. The PASI score ranges from 0 (clear skin) to 72 (maximum disease), a PASI score higher than 10 generally corresponds to moderate-to-severe disease.

Time frame:
From baseline to Week 4
Reported as:
Mean · Percentage change in PASI
Percentage Change in PASI From Baseline to Week 4
Percentage change in PASILEO 90100
Percentage Change in PASI From Baseline to Week 4-82.05 ± 17.87
SecondaryNumber of Subjects With 'Treatment Success' According to the Subject's Global Assessment of Disease Severity on the Body at Week 4

Number of subjects with 'treatment success' according to the Subject's Global Assessment of disease severity on the body at Week 4 in the full analysis set, defined as the 106 subjects assigned to treatment. Treatment success was defined as 'clear' or 'very mild' according to the Subject's Global Assessment of disease severity.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Subjects With 'Treatment Success' According to the Subject's Global Assessment of Disease Severity on the Body at Week 4
ParticipantsLEO 90100
Yes86
No17
SecondaryNumber of Subjects With 'Treatment Success' According to the Subject's Global Assessment of Disease Severity on the Scalp at Week 4

Number of subjects with 'treatment success' according to the Subject's Global Assessment of disease severity on the scalp at Week 4 in the full analysis set, defined as the 106 subjects assigned to treatment. Treatment success was defined as 'clear' or 'very mild' according to the Subject's Global Assessment of disease severity.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Subjects With 'Treatment Success' According to the Subject's Global Assessment of Disease Severity on the Scalp at Week 4
ParticipantsLEO 90100
Yes84
No19
SecondaryChange in Itch as Assessed on a Visual Analog Scale (VAS) From Baseline to Week 4

Change in itch as assessed on a visual analog scale (VAS) from baseline to Week 4 in the full analysis set, defined as the 106 subjects assigned to treatment. The assessments were made on a 100 mm (100 mm = 10 cm) horizontal VAS anchored at 0 ('no itch at all') and 10 ('worst itch you can imagine'). Subjects were asked to put a vertical line on the scale at the spot he/she felt best reflected the maximal itch intensity during the last 24 hours. The distance from 0 to the subject's indication line was measured in mm, thus higher scores indicated a worse outcome.

Time frame:
From baseline to Week 4
Reported as:
Mean · mm on VAS scale
Change in Itch as Assessed on a Visual Analog Scale (VAS) From Baseline to Week 4
mm on VAS scaleLEO 90100
Change in Itch as Assessed on a Visual Analog Scale (VAS) From Baseline to Week 4-32.5 ± 27.3

Adverse events

Collected over From Day -28 up to Day 56. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LEO 901000/106 (0%)0/106 (0%)22/106 (20.8%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventLEO 90100
Upper respiratory tract infectionInfections and infestations8/106
NasopharyngitisInfections and infestations4/106
AcneSkin and subcutaneous tissue disorders2/106
FolliculitisInfections and infestations1/106
ImpetigoInfections and infestations1/106
Oral herpesInfections and infestations1/106
PharyngitisInfections and infestations1/106
Pulpitis dentalInfections and infestations1/106
RhinitisInfections and infestations1/106
ErythemaSkin and subcutaneous tissue disorders1/106

Baseline characteristics

Of the 117 subjects who were enrolled in the trial and screened, 106 subjects met all inclusion criteria and none of the exclusion criteria. These 106 subjects comprise the Baseline Analysis Population.

Age, Continuous
Age, Continuous(years)LEO 90100
Mean14.2 ± 1.4
Sex: Female, Male
Sex: Female, Male(Participants)LEO 90100
Female61
Male45
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LEO 90100
Hispanic or Latino3
Not Hispanic or Latino103
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LEO 90100
White102
Native Hawaiian or Other Pacific Islander1
Other3
Region of Enrollment
Region of Enrollment(Participants)LEO 90100
Netherlands9
Romania32
United States2
Poland63
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)LEO 90100
Type I5
Type II44
Type III46
Type IV10
Type V1
Height
Height(cm)LEO 90100
Mean165.79 ± 9.77
Weight
Weight(kg)LEO 90100
Mean60.01 ± 14.41

1 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • Lucile Packard Children's Hospital at Stanford
    Palo Alto, California 94304, United States
  • Redwood Family Dermatology
    Santa Rosa, California 95403-2805, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059-3526, United States
  • Greenwich Village Dermatology
    New York, New York 10012, United States
  • Skin Speciality Dermatology
    New York, New York 10155, United States
  • Dermatology Treatment and Research Center PA
    Dallas, Texas 75230-5808, United States
  • UMC St Radboud
    Nijmegen, 6525, Netherlands
  • MULTIKLINIKA SALUTE Sp zo.o.
    Katowice, 40-123, Poland
  • Spitalul Clinic de Boli Infectioase si Tropicale
    Bucharest, 030303, Romania
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Mar 2018, 24 months.

Results were first posted in Jan 2019, 9 months after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 24 months is above that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2015
First posted
Mar 13, 2015
StartActual
Mar 2016
Primary completionActual
Mar 28, 2018
CompletionActual
Mar 28, 2018
Results first posted
Jan 15, 2019
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02387853
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Mar 13, 2015
Start date
Mar 2016
Primary completion
Mar 28, 2018
Completion
Mar 28, 2018
Results posted
Jan 15, 2019
Last update
Mar 10, 2025

Study contacts

M Seyger, MD
principal investigator · UMC St Radboud

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate

Start the discussion